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Background: Within a therapeutic gene by environment (G 9 E) framework, we recently demonstrated that variation
in the Serotonin Transporter Promoter Polymorphism; 5HTTLPR and marker rs6330 in Nerve Growth Factor gene;
NGF is associated with poorer outcomes following cognitive behaviour therapy (CBT) for child anxiety disorders. The
aim of this study was to explore one potential means of extending the translational reach of G 9 E data in a way that
may be clinically informative. We describe a ‘risk-index’ approach combining genetic, demographic and clinical data
and test its ability to predict diagnostic outcome following CBT in anxious children. Method: DNA and clinical data
were collected from 384 children with a primary anxiety disorder undergoing CBT. We tested our risk model in five
cross-validation training sets. Results: In predicting treatment outcome, six variables had a minimum mean beta
value of 0.5:5HTTLPR, NGF rs6330, gender, primary anxiety severity, comorbid mood disorder and comorbid
externalising disorder. A risk index (range 0–8) constructed from these variables had moderate a predictive ability
(AUC = .62–.69) in this study. Children scoring high on this index (5–8) were approximately three times as likely to
retain their primary anxiety disorder at follow-up as compared with those children scoring 2 or less. Conclusion:
Significant genetic, demographic and clinical predictors of outcome following CBT for anxiety-disordered children
were identified. Combining these predictors within a risk index could be used to identify which children are less likely
to be diagnosis-free following CBT alone and require longer or enhanced treatment. The ‘risk-index’ approach
represents one means of harnessing the translational potential of G 9 E data. Keywords: CBT, G 9 E, anxiety
disorders, child anxiety disorders.
Introduction
Gene–environment interaction (G 9 E) in the context
of psychological disorders is predominantly studied
within a diathesis stress framework, which proposes
that individuals carrying genetic vulnerabilities are
disproportionately likely to be adversely impacted by
an environmental stressor. However, this model
posits a truncated form of G 9 E, focusing exclu-
sively on adversity and negative outcomes, neglect-
ing positive environments and adaptive outcomes.
An alternative framework, the differential suscepti-
bility hypothesis, addresses this issue (Belsky &
Pluess, 2009). Individuals considered ‘vulnerable’
(strongly affected by adversity), may also benefit
most from supportive environments. Thus, individ-
ual differences in developmental plasticity may
result in genetic influences that act in a ‘for better
and for worse manner’ (Belsky & Pluess, 2009).
Derived from this framework is the concept of
vantage sensitivity, which proposes that individuals
will vary (for genetic and other reasons) in the extent
to which they gain benefit from positive and enrich-
ing environmental influences (Pluess & Belsky,
2012).
One example of vantage sensitivity could be
response to psychological intervention. For example,
while many people experience positive outcomes of
Cognitive Behaviour Therapy (CBT) for mood and
anxiety disorders, a large minority (35%–45%)
retains significant impairments. Very few studies
have investigated the source of this individual var-
iation in treatment response despite the potential for
stratified medicine and improved outcomes. Biolog-
ical measures, for example genetic or physiological
factors, have rarely been investigated as the source
of individual differences in response to psychological
interventions (Pluess & Belsky, 2012). Within the
child anxiety treatment field, clinical and demo-
graphic risk factors (such as age, gender, pretreat-
ment severity, comorbid disorders) have proven to be
modest and somewhat inconsistent predictors of
treatment response. This inconsistency may in part
arise from relatively small sample sizes and differ-
ences in assessment of outcome. One approach
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posits that the most likely source of predictors of
treatment response may be the origins of the disor-
der; that is, ‘cause should inform cure’ (Uher, 2008).
Genetic variants therefore represent plausible pre-
dictors of psychotherapy response. Testing for an
interaction between a therapeutic intervention and a
genetic variant represents a special case of G 9 E
(Uher, 2011) and provides an investigation of the
vantage sensitivity concept. In a therapeutic G 9 E
study, the environment is positive and predictable,
allowing for prospective analysis.
Very few studies have investigated genetic predic-
tors of individual differences in response to psycho-
logical therapy, a field we recently termed
‘therapygenetics’ (Eley et al., 2012).The most widely
studied marker to date is the serotonin transporter
promoter polymorphism (5HTTLPR). Two studies
have demonstrated that individuals with the low
expression short/short (SS) genotype show better
response to psychological therapy than those with
the intermediate/high expression genotypes (Eley
et al., 2012; Kohen et al., 2011), although one found
the reverse (Bryant et al., 2010), and six studies
showed no significant association (Bockting, Mock-
ing, Lok, Koeter, & Schene, 2012; Furmark et al.,
2010; Hedman et al., 2012; Lonsdorf et al., 2010;
Sakolsky et al., 2011; Wang et al., 2009). Associa-
tions with psychological treatment response have
also been investigated with other markers (Lester &
Eley, 2013). These include the serotonin transporter
intron 2 variable number tandem repeat (Kohen
et al., 2011; Sakolsky et al., 2011), 5-hydroxytryp-
tamine (serotonin) receptor 2A gene (Kotte, McQuaid,
& Kelsoe, 2007), tryptophan hydroxylase 2 gene
(Furmark et al., 2010), monoamine oxidase-A vari-
able number tandem repeat (Reif et al., 2013), cat-
echol-O-methyltransferase gene (Hedman et al.,
2012; Lonsdorf et al., 2010), nerve growth factor
gene (NGF) (Lester et al., 2012), brain-derived neu-
rotrophic factor gene (Fullana et al., 2012; Hedman
et al., 2012; Lester et al., 2012; Sakolsky et al.,
2010), and glutamate receptor, ionotropic kainite 4
gene (Sakolsky et al., 2010). To date, only two of
these candidate genes (5HTTLPR, NGF) have been
associated with treatment response following CBT
for child anxiety1.
At present, there is modest preliminary evidence
that G 9 E interactions are relevant not only in the
development but also the remission of psychopa-
thology. One method by which predictive power can
be potentially enhanced is through the use of ana-
lytic techniques that aggregate across multiple poly-
morphisms and/or genes into a single predictive
parameter or risk score. In the present study, we
present a first preliminary test of the combined
predictive value of both genetic variants and mea-
sures of demographic and clinical factors within a
therapeutic G 9 E design. With an end point focus
and hence greater clinical utility, our outcome was
nonremission from the primary anxiety diagnosis
following CBT in 384 children with anxiety disorders.
Our aim here was not to provide a definitive method
for determining risk scores, but to use this approach
to illustrate one way in which G 9 E data could be
repurposed to potentially provide clinical utility. Our
goal was to create a risk index in which scores of 0, 1
or 2 (to allow ease of use for clinicians) were allocated
for each clinical and genetic variable such that those
scoring high on this scale would be the individuals
least likely to benefit from current CBT protocols,
providing the opportunity to offer an enhanced
treatment from the outset. Although at present it is
expensive and impractical for clinicians to obtain
DNA samples from clients as part of routine practice,
in the future this may become a more viable option
given the momentum of the field of individualised
medicine.
Method
Participants
Three hundred and eighty-four children aged
6–13 years who met DSM IV criteria (American
Psychiatric Association, 1994) for a primary diagno-
sis of an anxiety disorder were selected. Participants
were excluded from the analyses if any of the genetic,
demographic or clinical variables (see below) were
missing or if they had significant physical/intellec-
tual impairment, psychoses and concurrent treat-
ment (N = 186, initial sample was 570).2 Subjects
were recruited from four trials at the Centre for
Emotional Health at Macquarie University, Sydney
and from two trials at the Berkshire Child Anxiety
Clinic, University of Reading (see online Appendix S1
for further information on treatment format).
Measures
Child diagnosis. Diagnoses were made at pretreat-
ment and follow-up with the Anxiety Disorders
Interview Schedule for DSM-IV, Parent and Child
versions (Silverman & Albano, 1996). Diagnoses and
Clinical Severity Ratings (CSR; 0–8) were assigned by
graduate or clinical psychologists based on compos-
ite parent/child report. Where the child met diag-
nostic criteria and received a CSR of 4 or more,
diagnosis was assigned. Children were allocated a
primary diagnosis (most interfering) as well as
comorbid diagnoses (see online Appendix S2 for
further information).
Parental symptoms. Parents completed the
Depression, Anxiety and Stress Scale (DASS-21)
(Lovibond & Lovibond, 1995), a self-report measure
of symptoms over the past week. Three 7-item scales
were created for stress, anxiety and depression
(range 0–21); internal consistency was .85, .76 and
.90 respectively. To identify parents with significant
symptoms, we used the cut-offs for the ‘severe’
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category (21, 15 and 26 for depression, anxiety and
stress respectively). Parents were classified as
affected if they scored above the cut-off for any of
the three scales (mothers: 20.9% affected; fathers:
18.7% affected). Parental caseness scores were 0
(neither parent affected, 67.4%), 1 (1 parent, 26.6%)
or 2 (both parents, 6.0%).
Ethnicity. Child ethnicity was based on reports of
grandparent ancestry. As we wanted to develop a
risk index of broad clinical utility, we included all
individuals in our analyses regardless of ethnicity.
The percentage of participants within each ethnic
subgroup was: white European (62.8%); African or
Caribbean (0.3%); Asian (1.3%); Arab and Middle
Eastern (1.6%); Mixed (7.6%) and Ancestry unknown
and missing data (26.6%).
Genotyping
GenomicDNAwas extracted frombuccal swabs using
established procedures (Freeman et al., 2003) (See
online Appendix S3 for further information on geno-
typing procedure). Genotyping of 5HTTLPR was per-
formed by polymerase chain reaction with the
amplified products (S-469 bp, L-512 bp) separated
by electrophoresis on a 3.5% agarose gel and stained
with ethidium bromide. For NGF rs6330, genotyping
was performed using the Sequenom MassARRAY 
iPLEX Gold technology (Sequenom, San Diego, CA,
USA). Genotype distribution conformed to the Hardy–
Weinberg Equilibrium for 5HTTLPR (SS: 21.1%; LS:
47.4%; LL: 31.5%; v21 = 0.67, p = .414 and NGF
rs6330 TT: 21.6%; CT: 48.4%; CC: 30.0%;
v21 = 0.23, p = .632).
Procedure
Ethical approval was received from Human Ethics
and Biosafety Committees at both sites. Parents
provided informed consent, children provided assent.
Buccal swabs were collected either at the clinic or
through the post. Families provided data at pre-,
post- (N = 373; 97.1%) and follow-up (N = 384;
100%). The follow-up point differed across trials:
52 were assessed at 3 months, 307 at 6 months
and 25 at 12 months.
Statistical analysis
We classified treatment outcome on the absence/
presence of the primary anxiety disorder. We
focused on the outcome at follow-up as this was
where we saw the strongest effect in our previous
studies (Eley et al., 2012; Lester et al., 2012). To aid
in computing a cumulative risk score for nonremis-
sion (primary anxiety disorders still present at
follow-up), all predictor variables were di- or trichot-
imised. We focused on the alleles associated with
risk for poor treatment outcome, the L allele for
5HTTLPR and the C allele for NGF rs6330. A reces-
sive model was used for 5HTTLPR (i.e., SS coded as
0; SL/LL coded as 1), and an additive model for NGF
rs6330 (TT coded as -1; CT coded as 0 and CC coded
as 1 [For the purposes of calculating the risk score in
later analyses, TT was scored as 0, CT was scored as
1 and CC was scored as 2]) in line with previous
analyses (Eley et al., 2012). The remaining variables
were coded as follows: age (0 = lower 50%, 1 = upper
50% of distribution); gender (0 = male, 1 = female);
pretreatment anxiety severity (0 = CSR of 4–6,
1 = CSR of 7–8); comorbid mood disorders
(0 = absence, 1 = presence); comorbid externalising
disorders (0 = absence, 1 = presence) and parental
psychopathology (0 = neither parent affected, 1 = 1
parent affected, 2 = both parents affected).
We tested the predictive performance of the risk
index using a cross-validation technique (Hastie,
Tibshirani, & Friedman, 2009).3 We performed five
rounds of cross-validation using a repeated random
subsampling validation method. On each round, the
sample was partitioned into a training set (80% of
the sample) and a validation set (20% of the sample).
For each round of cross-validation, multiple linear4
regression analyses with robust standard errors
were modelled in the training set to provide param-
eter estimates (unstandardised beta coefficients) for
each predictor of treatment outcome (coded
0 = absence of primary anxiety diagnosis, i.e. remis-
sion, and 10 = presence of primary anxiety diagno-
sis, nonremission).5 Risk scores were then
calculated for each individual in the validation set
using two methods: (a) by assigning a score for each
predictor variable from the unstandardised beta
coefficient estimated in the training set and (b) by
assigning a score for each predictor using a mean
unstandardised beta coefficient computed across the
five training sets and then rounded to the nearest
integer. This latter approach is appealing as by
averaging parameter estimates across training sets,
variability is reduced. Furthermore, while rounding
parameter estimates may somewhat reduce preci-
sion, it may increase clinical utility through its
simplicity. In both approaches, the risk score took
the following form:
risk score ¼b1  5HTTLPRþ b2  NGFþ b3  Age
þ b4 Genderþ b5  Severity
þ b6  ComorbidMood
þ b7  ComorbidExternalising
þ b8  ParentalPsychopathology
Predictive accuracy was assessed in each valida-
tion set by testing the extent to which the risk score6
correctly classified remission and nonremission.
Area under the curve (AUC) values were computed
using nonparametric receiver operating characteris-
tic analyses. Finally, we report exploratory analyses
that investigate the extent to which the rounded risk
© 2013 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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score was associated with treatment outcome in the
entire sample (N = 384).
Results
Descriptive statistics
Table 1 provides descriptive data and test statistics
for the genetic, demographic and clinical predictors
comparing training and validation sets for each of
the five cross-validation partitions. Within each
cross-validation partition, the training and valida-
tion sets did not differ significantly on any variables
reported. More broadly, rates of remission did not
differ significantly between the Reading and Sydney
sites, v2 (1) = 0.81, p = .37. The rates of remission for
the entire sample were 60.9% (n = 234).
Predicting treatment outcome in the training set
Table 2 reports unstandardised beta coefficients for
each predictor variable, and p values. We also report
mean unstandardised beta coefficients calculated
across the five cross-validation partitions, and
rounded beta values based on these mean beta
coefficients.
Genetic, demographic and clinical predictors in
combination significantly predicted treatment out-
come, with all model p values <.05. The proportion
of the variance in treatment outcome accounted for
by the model (R2) approximated 8%. The most
consistent predictor of treatment outcome was
NGF rs6330 genotype, which significantly predicted
treatment outcome in all five data sets (p values
from .008 to .03). With each extra C allele, partic-
Table 1 Sample characteristics for the entire sample and test statistics comparing training and validation sets for each
cross-validation sample
Entire sample (N = 384)
Cross-
validation
1
Cross-
validation
2
Cross-
validation
3
Cross-
validation
4
Cross-
validation
5
Pretreatment (N = 384) v2/t p v2/t p v2/t p v2/t p v2/t p
Child ancestrya (white; other; missing) 62.8; 10.7; 26.6 4.09 .13 0.38 .83 3.58 .17 1.92 .38 1.01 .61
Child ageb 9.34 (1.87) 0.43e .51 0.15 .70 0.43 .51 0.44 .51 0.15 .70
Child gender (M:F)c 195: 189 0.55 .46 0.05 .82 0.29 .59 1.09 .30 0.29 .59
Primary anxiety severityd 6.30 (.86); 43.2 0.01e .94 1.85 .17 0.01 .94 0.91 .34 0.19 .66
5HTTLPR genotypea(LL; LS; SS) 31.5; 47.4; 21.1 1.99 .37 0.74 .69 0.97 .61 2.28 .24 0.89 .64
NGF rs6330 genotypea(CC; CT; TT) 30.0; 48.4; 21.6 1.50 .47 1.83 .40 0.19 .91 1.00 .61 1.29 .53
Comorbid mood disordera 8.9 1.60 .21 0.01 .94 0.01 .94 0.13 .71 0.96 .33
Comorbid externalising disordera 20.0 0.25 .62 0.02 .89 2.11 .15 0.21 .65 0.02 .89
Maternal DASS affecteda(N = 382) 20.9 1.67 .20 0.84 .36 0.35 .56 0.08 .77 0.43 .51
Paternal DASS affecteda(N = 363) 18.7 0.00 .96 0.61 .44 1.40 .24 0.20 .66 0.10 .75
Parental DASS affecteda
(0 parent; 1 parent; 2 parents)
67.4; 26.6; 6.0 2.02 .36 0.20 .91 1.89 .39 0.05 .97 1.70 .43
Post-treatment (N = 373)
Primary anxiety severityb 3.42 (2.06) 0.59 .56 0.12 .91 0.00 .99 0.34 .73 0.54 .59
Primary anxiety remissiona 50.7 0.28 .60 0.42 .52 0.15 .70 0.60 .44 0.00 .99
Follow-up (N = 384)
Primary anxiety severityb 2.85 (2.03) 0.26 .79 0.93 .35 0.68 .50 0.95 .34 1.52 .13
Primary anxiety remissiona 60.9 0.29 .59 1.05 .31 0.58 .45 1.14 .29 0.29 .59
Data reported: apercentage; bMean (SD); cN; dMean (SD); % in severe primary anxiety severity category (CSR 7–8). Analyses: eTest
statistics compare frequencies of a binary variable (e.g., young versus old age group; severe versus moderate primary anxiety
severity).
Table 2 Unstandardised beta coefficients for demographic, clinical and genetic predictors in each training set and mean beta values
calculated across the five training sets
Training 1 Training 2 Training 3 Training 4 Training 5 Mean b
Model p value .0001 .009 .002 .001 .002
R2 .08 .07 .08 .08 .08
b p b p b p b p b p Mean Rounded
5HTTLPR 1.13 .09 1.15 .09 .44 .51 .91 .19 1.09 .10 0.94 1
NGF .86 .02 .83 .03 .89 .02 .98 .008 .99 .009 0.91 1
Age .01 .98 .12 .83 .51 .38 .20 .74 .29 .62 0.09 0
Gender .63 .26 .86 .13 .52 .35 1.12 .05 .71 .20 .77 1
Primary anxiety severity 1.10 .06 1.22 .03 .87 .13 1.09 .06 1.12 .05 1.08 1
Comorbid mood 1.76 .07 1.12 .28 2.47 .02 1.29 .20 1.51 .17 1.63 2
Comorbid externalising 1.45 .05 1.16 .11 1.19 .11 .91 .20 1.05 .15 1.15 1
Parental caseness .26 .58 .27 .57 .13 .79 .25 .61 .16 .76 .11 0
Constant 1.64 .03 1.50 .06 2.59 .001 1.70 .04 2.02 .01
Bold values indicate beta values significant at p > .05
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ipants were at a significantly greater risk of retain-
ing their primary anxiety diagnosis at follow-up.
Gender, primary anxiety severity, comorbid mood
disorders and comorbid externalising disorders also
significantly predicted treatment outcome, albeit
not consistently across the five training sets. Where
these variables were significant predictors, poor
outcome was associated with being female, greater
anxiety severity pretreatment and the presence of
comorbid mood and externalising disorders. Paren-
tal psychopathology, 5HTTLPR genotype and age did
not make a significant contribution to the prediction
of treatment outcome in these analyses. However,
the purpose of this step was not to determine
statistical significance per se but, instead, to
estimate effect sizes for each predictor, irrespective
of significance level, that could then be carried
forward to calculate a risk score in the validation
sets.
Calculating and testing the predictive fit of a risk
score in the validation set
As described above, we calculated two risk score
variants: sample specific and rounded risk scores. To
test how well the risk scores predicted outcome, we
conducted logistic regression analyses with robust
standard errors with risk score entered as a contin-
uous predictor of presence (1) or absence (0) of
primary anxiety disorder at follow-up. Table 3 (top
panel) reports descriptive statistics for the sample
specific risk score, odds ratios, p values and area
under the curve (AUC) values with associated
confidence intervals.
There was some variability in the predictive
performance of the sample specific risk score
across the five validation sets, with two of the five
models providing statistically significant prediction
(p < .05) of treatment outcome in the validation
data set. However, as anticipated, all models
reported odds ratios exceeding 1 (range 1.32–
1.69), indicating that as risk score increased, the
odds of nonremission (i.e., still having primary
anxiety diagnosis) increased. For example, an odds
ratio of 1.69 was identified in validation set 2: this
indicates that the odds of nonremission increased
by 1.69 times for every single point increment on
the risk score. For the sample specific risk score,
AUC7 ranged from 0.62 to 0.68 with a mean value
of 0.65.
Table 3 (bottom panel) reports summary statistics
for the cross-validation rounded risk score. Four of
the five models attained statistical significance. All
models reported odds ratios exceeding 1 (range 1.38–
1.70), again indicating that as the rounded risk score
increased, the odds of nonremission also increased.
For example, an OR of 1.70 was reported in valida-
tion set 2 indicating that the odds of nonremission
increased by 1.7 times for every point increment on
the risk score. AUC ranged from 0.65 to 0.69, with a
mean AUC of 0.66. The rounded risk score and
sample specific risk score therefore discriminated
between remission and nonremission to a similar
extent. Age and parental caseness had rounded
scores of zero indicating that they did not contribute
to prediction of outcome over and above the other
variables in the model. As a result of the zero scores,
age and parental caseness do not contribute to the
risk index.
Characterising treatment outcome as a function
of risk score in the entire sample
As a final step, we performed exploratory analyses to
investigate the extent to which the rounded risk
score was associated with treatment outcome in the
entire sample. From a statistical perspective, this
has the obvious limitation that it is not an indepen-
dent sample from that in which the risk score was
developed. However, these exploratory analyses were
undertaken solely to demonstrate the potential clin-
ical utility of the risk score approach for predicting
treatment outcome. Figure 1 depicts the distribution
of risk scores in remitters and nonremitters. The
distribution of risk scores was shifted to the right for
nonremission compared with remission with a mean
Table 3 Model fit statistics and logistic regression analyses using the sample specific and rounded risk score as a predictor of
treatment outcome in the five validation sets
Validation 1 Validation 2 Validation 3 Validation 4 Validation 5
Sample specific risk score
Mean 3.07 (1.39) 2.86 (1.40) 2.19 (1.29) 3.32 (1.38) 3.16 (1.41)
Range .01–7.46 0–7.29 .51–5.39 0–6.19 0–7.17
OR (95% CI) 1.32 (.90–1.94) 1.69 (1.17–2.43) 1.34 (.94–1.93) 1.41 (.98–2.03) 1.50 (1.05–2.16)
p .15 .005 .10 .06 .03
AUC .65 (.52–.78) .68 (.56–.81) .62 (.49–.75) .63 (.50–.76) .65 (.52–.77)
Rounded risk score
Mean 3.06 (1.35) 2.97 (1.55) 3.25 (1.37) 3.16 (1.41) 3.36 (1.49)
Range 0–7 0–8 0–6 0–6.0 0–8
OR 1.38 (.92–2.06) 1.70 (1.22–2.38) 1.58 (1.09–2.29) 1.49 (1.03–2.14) 1.49 (1.06–2.08)
p .12 .002 .02 .03 .02
AUC .65 (.53–.78) .69 (.57–.81) .67 (.55–.79) .65 (.53–.78) .65 (.52–.77)
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risk score of 3.64 (SD 1.45) and 2.87 (SD 1.30),
respectively, t(382) = 5.44, p < .001, d = 0.57.
Figure 2 reports the percentage of participants
with each risk score who retained their primary
anxiety at follow-up. Given the low number of
participants for some scores within the scale, we
divided the sample into the following four risk
categories: 0–2, 3, 4 or 5–8.
Nonremission increased in a linear manner with
each risk category with just 23% of those scoring 0–2
retaining their primary anxiety disorder at follow-up
compared with 62.3% of those scoring 5–8. Risk
score significantly predicted treatment outcome at
follow-up (OR = 1.51 [95% CI: 1.28–1.77], p < .001).
AUC was also commensurate to that seen in the
validation sets (0.66).8 (see online Appendix S4 for
further information on sensitivity and specificity
results.)
Discussion
This paper presents a novel risk score approach to
combining genetic, demographic and clinical data to
predict nonremission to psychological therapy for
child anxiety disorders. In doing so, we illustrate one
clinically informative method of repurposing G 9 E
data that may assist in the identification of individ-
uals who may require an enhanced treatment pack-
age. Our combined clinical trial data set also
permitted greater clarification regarding the impor-
tance of clinical factors in predicting remission of
anxiety diagnoses. We found that greater pretreat-
ment severity, comorbid mood disorders, comorbid
externalising disorders and female gender were all
significantly associated with poorer remission rates
in at least one of our 5 validation sets when
controlling for other variables (including genetic
factors). In line with our hypothesis, the risk score
combining genetic and demographic/clinical factors
had an odds ratio significantly greater than 1 in all
analyses. This indicates that the odds of nonre-
mission increased for every one-point increment on
the risk score. The risk index showed moderate
predictive ability, with a mean AUC of .65 and .66
using the sample specific and rounded risk scores
respectively. Finally, in the entire sample, the risk
score was significantly higher in nonremitters than
remitters and those with scores in the highest risk
band (5–8) were almost three times as likely not to
remit following treatment as those in the lowest band
(0–2).
Implications: predictors of treatment outcome
Previous research examining nongenetic predictors
of treatment outcome for child anxiety has been
limited by low power, resulting in inconsistent
findings. In our larger sample, we were able to
examine the role of demographic and clinical factors
whilst also taking into account preliminary genetic
findings. As previously demonstrated (see Rapee,
Schniering, & Hudson, 2009), higher pretreatment
severity of child anxiety predicted poorer outcome,
even after accounting for both 5HTTLPR and NGF
rs6330 genotypes. In line with some (Liber et al.,
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2010) but not all previous research, comorbid mood
and externalising disorders also significantly
predicted poorer outcome over and above all
other variables. Previous studies have produced
inconsistent findings with regards to the impact of
nonanxiety comorbidity on treatment outcome, pos-
sibly due to their low frequency in children. The
discrepant findings may also be due to different
definitions of treatment response (e.g., diagnostic
status at outcome versus change in symptom
severity). The findings in this study are unique in
showing that, even after accounting for pretreat-
ment severity, children with comorbid nonanxiety
diagnoses have significantly worse end points fol-
lowing treatment than children without comorbid
diagnoses.
Finally, we also demonstrated that female gender
was associated with poor treatment outcome. The
majority of studies comparing treatment outcome
for girls and boys have shown that gender does not
moderate treatment outcome (Rapee et al., 2009).
The current findings cannot be explained by
increased severity or comorbidity as the effect was
evident after controlling for both. It is possible that
factors associated with increased anxiety in girls
also increase the likelihood of nonremission. This
finding requires replication and further investiga-
tion.
Of note, neither age nor parental psychopathology
were significant predictors of outcome, although our
sample was restricted to children 13 years and
under. Previous evidence regarding the role of
parental psychopathology in treatment outcome fol-
lowing CBT for child anxiety is mixed (Rapee et al.,
2009). In our analyses, parental psychopathology
was not significant in any of the five validation sets,
and the rounded mean beta coefficient was zero. If
entered alone, parental psychopathology did predict
outcome in this sample, but this effect was no longer
present once other variables were included. How-
ever, we also note that our measure of parental
psychopathology relied solely on a self-report ques-
tionnaire which may have led to underreporting of
parent symptoms, thus reducing the strength of this
variable as a unique predictor of child outcome
(Bogels & Brechman-Toussaint, 2006). Measure-
ment of parental psychopathology using structured
diagnostic interviews may result in a more accurate
picture of symptoms.
Implications: risk index for poor treatment outcome
Our risk index created from genetic, demographic
and clinical factors was moderately good at predict-
ing remission at follow-up. These results provide
early promise that combining genetic information
with clinical and demographic risk factors may be an
informative approach to predicting individual differ-
ences in response to psychological treatment. Our
data also support for the idea that genetic factors
(over and above demographic and clinical variables)
moderate response to a positive environmental
influence, namely psychological therapy (Pluess &
Belsky, 2012). Our risk index had similar predictive
ability regardless of whether we used the sample
specific or rounded beta coefficients. The next step is
clearly to replicate these results, and to extend them,
taking into account other potential predictors of
nonremission, including additional genetic polymor-
phisms. What is more encouraging is that those in
the highest band of our risk index were almost three
times as likely not to remit following treatment as
those in the lowest band, suggesting that the
approach is worth pursuing further.
Limitations
We note a number of limitations. First, our sample
remains small for a G 9 E study, even though it is
the largest of its kind to date. Second, we recruited
from six trials across two sites. However, not only
does this make the data a closer representation of
reality than utilising data from a single trial, it also
means that our findings rose above the noise our
sampling strategy inevitably incurred. Third, we
focus here on the follow-up data, as our previous
papers indicate that the effects of genotype occurred
at this time-point (Eley et al., 2012). We note,
however, that the follow-up time-point was not
consistent across participants, which may have
influenced our findings. We have previously dis-
cussed that we believe the late emergence of a
significant genetic effect may be explained by con-
tinued practising of techniques learned during CBT.
It is possible that what our risk index measures is
the likelihood of a child continuing to benefit from
treatment once it has ended. Fourth, this study
focuses exclusively on two candidate genes. We
anticipate in the future that multiple genes (of very
small effect) will be identified to predict treatment
outcome. The field of therapygenetics is in its infancy
and future work will be better placed to use poly-
genic risk scores. Finally, although our sample size
allowed a greater number of children with mood
disorders to be identified compared with smaller
studies, there remained a low prevalence of mood
disorders (8.9%), resulting in large standard errors
around their odds ratios. Replication of these find-
ings will be important.
In conclusion, we have illustrated that combining
genetic, demographic and clinical data into a risk
score is an informative means of repurposing G 9 E
data. Our data provide preliminary evidence that
children with a high number of genetic, demographic
and clinical risks are least likely to benefit from
standard CBT. If replicated, a risk index using both
genetic and clinical information could be applied in a
clinical context to help decide whether a child is
likely to benefit from standard CBT alone or whether
enhanced treatment is required.
© 2013 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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Note
1 GRIK4 was associated with treatment outcome in a
sample of anxiety-disordered children receiving
CBT, Sertraline or CBT+Sertraline. However, it
remains unclear whether GRIK4 interacts with
treatment type (Sakolsky et al., 2010).
2 Note, missingness was primarily a result of missing
follow-up or parental DASS data.
3 Cross-validation involves partitioning a data set into
training and validation sets. For each partition, a
model is fitted within the training set and then the
predictive performance of the model is assessed in
the validation set. Multiple rounds of cross-valida-
tion are undertaken using different partitions to
reduce variability and the validation results are
averaged.
4 Linear rather than logistic regression was used to
obtain additive rather than multiplicative parameter
estimates that could easily be combined into a risk
score.
5 The scale was modified here so the beta values
rounded to 1 rather than .1. The scale is reverted to
0 and 1 for analyses using the validation data sets.
6 The constant was not included in our risk score
computations as it is irrelevant for discrimination
between those who do and do not remit following
treatment.
7 AUC measures the discriminative ability of the risk
score to correctly classify those with and without
their primary anxiety diagnosis. The AUC repre-
sents the proportion of randomly drawn pairs,
consisting of one individual with their primary
anxiety diagnosis and one individual without their
primary anxiety diagnosis who would be correctly
classified as such on the basis of their risk score.
The participant with the higher risk score should
be the one from the group with their primary
anxiety diagnosis remaining.
8 We tested this in the white only subset and the index
performed in a similar manner [OR = 1.73 (95% CI:
1.40–2.15), p < .001; AUC = 0.70].
Correspondence
Jennifer L. Hudson, Centre for Emotional Health,
Department of Psychology, Macquarie University,
Sydney, NSW 2109, Australia; Email: jennie.hudson@
mq.edu.au
Kathryn J. Lester, King’s College London, MRC Social,
Genetic and Developmental Psychiatry Centre, Institute
of Psychiatry, London, UK; Email: kathryn.lester@kcl.
ac.uk
Key Points
• We created a risk index from genetic, demographic and clinical factors to predict remission following CBT for
child anxiety.
• The odds of nonremission increased for every one-point increment on the risk score.
• 5HTTLPR and NGF rs6330 genotypes, pretreatment severity of child anxiety, comorbid mood and externalising
disorders and gender predicted treatment outcome.
• Combining these predictors within a risk index could be used to identify which children are less likely to be
diagnosis-free following CBT alone or thus require longer or enhanced treatment.
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